Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'
August 4, 2022 11:06 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and {REMOVEPT} price target on Intellia Therapeutics (NASDAQ: NTLA)
The analyst comments "NTLA remains on track to present initial data from NTLA-2001 in ATTR-CM and NTLA-2002 in HAE in H2:22. The... More
RBC Capital on Intellia Therapeutics (NTLA) as Shares Like Over 10%: 'Stock Reaction Overdone'
August 4, 2022 10:17 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $150.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA announced today a new case of possibly drug-related liver enzyme elevation at 1 mg/kg and is backing off the dose going forward from... More
Intellia Therapeutics (NTLA) Misses Q2 EPS by 5c
August 4, 2022 7:55 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.33), $0.05 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $14.03 million versus the consensus estimate of $9.42 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
... More